最高涨幅1824%，2025年哪些医药股涨疯了

Group 1 - The core viewpoint of the article highlights the significant rise in Chinese pharmaceutical stocks, with many companies experiencing substantial stock price increases, referred to as "X-fold stocks" [1] - The article discusses the emergence of several "three-fold," "four-fold," and even "ten-fold" stocks in the Hong Kong market, driven by various factors including overseas product licensing and market recovery [1] Group 2 - Beihai Kangcheng, once known as the "first stock in rare diseases," has struggled financially but saw a turnaround after a share subscription agreement with Baiyang Pharmaceutical, leading to a significant increase in its stock price [5][6][7] - Sanleaf Biotech, which went public in 2021, has faced challenges in the vaccine market, resulting in continuous losses, but is focusing on developing RSV vaccines as a potential growth area [8][9] - Yaojie Ankang experienced a dramatic stock price increase shortly after its IPO, driven by speculative trading, but has since seen a decline in its market value [9][10] - Hecui Pharmaceutical has established itself as a leader in business development (BD) transactions, achieving significant revenue through collaborations with multinational pharmaceutical companies [10][11][12] - Xuan Bamboo Biotech benefited from a new subscription mechanism in Hong Kong, achieving an oversubscription of nearly 5000 times, and has a solid pipeline of products [13][14] - Deqi Pharmaceutical has regained institutional recognition and is expected to see a valuation rebound due to promising clinical data from its drug candidates [15][16] - Jako Pharmaceutical successfully developed a KRAS G12C drug, marking a significant achievement in targeting previously deemed "undruggable" targets [17] - Rongchang Biotech anticipates a return to profitability in 2025, driven by strong sales growth of its core products [18][19][20] - Paige Biopharma is focusing on the GLP-1 market, with several drugs in development, capitalizing on the growing demand for weight loss medications [21] - Baiaosaitu, a CRO, has differentiated itself in the market by integrating AI into its drug development processes, showcasing a unique growth trajectory [22][23][24]